Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Hung Le(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Gary B. Chisholm(Buck Institute for Research on Aging), Patrick Hwu(Moffitt Cancer Center), Revathy B. Iyer(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center)
Cited by 31
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551